Novo Nordisk's $16.5B Catalent Buyout

This is a news story, published by CNBC, that relates primarily to Novo Nordisk's news.

Novo Nordisk's news

For more Novo Nordisk's news, you can click here:

more Novo Nordisk's news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

CNBC news

For more news from CNBC, you can click here:

more news from CNBC

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Novo Holdings

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest last hurdle Novo Holdings news, Novo Nordisk news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Novo

CNBC

•

Health

Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing

Summary

Nutrition label

83% Informative

Danish drugmaker Novo Nordisk's parent company got approval from European antitrust regulators last week to move forward with its proposed $16.5 billion buyout of U.S.-based drug manufacturer Catalent .

The deal could boost availability of the drugs because Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens for Wegovy and Ozempic .

Competing drugmakers have pushed back on the deal.

Nobel Laureates write to the U.S. Senate to oppose the confirmation of Robert Kennedy Jr. as Secretary of the Department of Health and Human Services .

They say Kennedy has been an opponent of many health-protecting and life-saving vaccines, such as those that prevent measles and polio.

The leader of DHHS should continue to nurture and improve--- not threaten--- these important and highly respected institutions and their employees.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive